Eli Lilly's $23B Q2 Revenue Breaks Records | Pharma and Biotech Daily - Pharma and BioTech Daily

Summary4 min read

Pharma & Biotech Daily — Episode Summary

Episode: Eli Lilly's $23B Q2 Revenue Breaks Records | Pharma and Biotech Daily
Date: August 6, 2026

Overview of the Episode

This episode delivers a concise rundown of the most vital developments in pharma and biotech as of early August 2026. The discussion is anchored by Eli Lilly’s record-shattering $23 billion Q2 2023 revenue, powered by successful launches in the metabolic diseases space. Other significant topics include shifting trends in obesity therapeutics, major advances in HIV prevention, the expanding role of artificial intelligence, novel oncology partnerships, regulatory maneuvers, and noteworthy investment activity.

Key Discussion Points & Insights

1. Eli Lilly’s Record Financial Performance

[00:26] Eli Lilly posted an unprecedented $23 billion in Q2 2023 revenue.
This gain is credited primarily to the success of Mounjaro and Zepbound in metabolic disease treatments.
Foundio’s slower rollout highlights ongoing challenges despite the boom in metabolic therapy markets.
Quote:

“This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions.” — Host, [00:31]

2. Obesity Treatment Landscape

Novo Nordisk’s WeGovy remains the market leader, even as Eli Lilly’s entrants like Foundiol attempt to claim market share.
A trend toward increased patient preference for oral medications over injectables is noted.

3. HIV Franchise Expansion and Legal Wins

Gilead Sciences’ HIV prevention business has exceeded $1 billion in quarterly sales.
Legal victories maintaining their tenofovir-based treatments secure future innovation and solidify Gilead’s leadership.
Quote:

“Gilead also remains a focal point with its HIV pre exposure prophylaxis franchise, reaching sales milestones amid legal victories defending their tenofovir based treatments.” — Host, [01:12]

4. Artificial Intelligence in Drug Discovery & Development

ICON and Anthropic’s partnership aims to accelerate development timelines via advanced AI.
Phylo and Chugai are employing AI to streamline cancer drug discovery workflows.
This signals a broader industry move toward AI-enhanced drug development, especially in oncology.

5. Strategic Oncology Collaborations

Amplia Therapeutics & Eli Lilly are trialing combination therapy for non-small cell lung cancer.
Avexta Bio & Roche are collaborating on metastatic breast cancer research.
The focus is: combination therapies and precision medicine to improve outcomes.
Quote:

“These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes.” — Host, [02:00]

6. Biologics Manufacturing and Local Partnerships

AstraZeneca and CSPC Pharmaceutical’s deal enhances biologics production capacity in China, showing the significance of local manufacturing bases.

7. Rare Disease Regulatory Updates

Arrowhead Pharmaceuticals’ acquisition of an FDA Rare Pediatric Disease Priority Review Voucher for Plazaserin could fast-track life-saving therapies to market.

8. Clinical and Regulatory Setbacks

Novo Nordisk’s Cagrosema failed its primary endpoint in a Phase 3 diabetes trial, highlighting the difficult road for combo metabolic drugs.
Eli Lilly discontinued its GbA1 gene therapy program.

9. Pipeline Rationalization & Clinical Milestones

Amgen is dropping its early-stage obesity drug to focus on next-gen assets, such as Meritide.
Amgen’s Repatha is enjoying renewed clinical and commercial interest due to robust cardiovascular outcomes.

10. Regulatory Spotlight

Merck’s Liphendra is under an FDA pilot program for complex product validation, and could redefine the PCSK9 inhibitor category.

11. Industry Investment & Deals

Atovia Therapeutics raised $289 million via IPO for dermatology advances.
Expedition Therapeutics secured a $115 million Series B, targeting respiratory therapies.
Johnson & Johnson is deepening gene therapy investments, notably with CEL Biomedicines’ CAR T ventures.

12. Regulatory and Statistical Hurdles

Capricor’s cell therapy programs suffered an FDA review setback due to statistical challenges.

13. Emergence of Personalized & Safer Therapies

New personalized genetic therapy centers are emerging.
Continued research and innovation into safer CAR T-cell therapies.
Quote:

“The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer car-t therapies progresses.” — Host, [03:32]

Notable Quotes & Memorable Moments

Eli Lilly’s Q2 achievement:
“Record breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape…” — Host [00:31]
On industry-wide strategic focus:
“These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes.” — Host [02:00]
Personalized medicine trend:
“The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer car-t therapies progresses.” — Host [03:32]

Timestamps for Key Segments

[00:26] – Eli Lilly Q2 earnings and competitive landscape
[01:12] – Gilead’s HIV franchise and legal wins
[01:40] – AI-driven partnerships in pharma
[02:00] – Cancer collaborations and industry focus
[02:40] – Biologics manufacturing and regional production
[03:00] – Rare disease voucher and regulatory innovation
[03:32] – Personalized therapies and innovation outlook

Tone & Style

The episode is fast-paced and information-rich, tailored for a savvy professional audience. Language is precise and matter-of-fact, reflecting the strategic and scientific sophistication of the content.

Conclusion

This briefing reflects the sector’s ongoing innovation, strategic pivoting, and regulatory navigation. It spotlights historic financial milestones, the surge of AI collaborations, pipeline strategic shifts, and the acceleration toward individualized, precision medicine—all against a backdrop of fierce competition and constant regulatory scrutiny. The episode is essential listening for anyone building, operating, or investing in life sciences.

Loading summary

Transcript2 lines

[00:00]
A
Biotech Daily is now open for sponsors and job of the Week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week, or promote an open role, all directly by visiting sponsor O with AI that's sponsor Owith AI.
[00:20]
B
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we delve into the intricate web of scientific advancements, regulatory updates and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundio highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's WeGovy continues to dominate despite new entrants like Eli Lilly's Foundiol. This scenario reflects growing patient preference for oral medications over injectables. Gilead Science's HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre exposure prophylaxis franchise, reaching sales milestones amid legal victories defending their tenofovir based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. ICON's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes in oncology. Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non small cell lung cancer, while Avexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals acquisition of an FDA Rare Pediatric Disease Priority Review voucher for Plazaserin represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrosema failed to achieve its primary endpoint in a phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its phase 1/2 trial for GbA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Meritide. This move aligns with broader trends, prioritizing candidates with significant potential impact on patient care. Amgen's Repatha is experiencing renewed interest due to positive cardiovascular risk reduction data showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's Liphendra has been spotlighted by the FDA as part of its complex new product validation pilot program. This positions Lipfendra as a potential game changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Atovia Therapeutics $289 million IPO and Expedition Therapeutics $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic, with Johnson and Johnson investing heavily in gene therapy ventures like CEL Biomedicines for car T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer car t therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily. Stay tuned for more insights from the world of pharmaceuticals and biotech.